News - Sanofi, Lantus

Filter

Current filters:

SanofiLantus

Popular Filters

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA

08-07-2013

US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

More news from American Diabetes Association meeting

13-06-2012

Ongoing news from the American Diabetes Association meeting in Philadelphia (see also The Pharma Letter…

Boehringer IngelheimDiabetesEli LillyLantusLY2605541PharmaceuticalResearchSanofi

Sanofi inaugurates Lantus SoloSTAR Pen assembly plant in China

28-05-2012

French drug major Sanofi (Euronext: SAN) revealed this morning that it has inaugurated a new assembling…

Asia-PacificDiabetesLantusMarkets & MarketingPharmaceuticalSanofi

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus

07-11-2011

Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting

13-09-2011

French drug major Sanofi (Euronext: SAN) has reported positive results from the GetGoal-F1 study with…

DiabetesLantusLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Back to top